MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
May 15, 2019 17:07 ET
|
MacroGenics, Inc.
Study meets first sequential primary endpoint of progression-free survival (PFS) in head-to-head with current standard of care (trastuzumab and chemotherapy)Oral abstract will be presented at American...
MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results
May 01, 2019 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, Md., May 01, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of First Quarter 2019 Financial Results Conference Call
April 24, 2019 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, April 24, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Reports Presentation of Data at the AACR Annual Meeting 2019
April 03, 2019 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, April 03, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
April 02, 2019 17:00 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, April 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...